Watson Pharmaceuticals Inc. (NYSE:WPI) recently announced that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for the approval of a generic version of Shire’s (NASDAQ:SHPGY) ulcerative colitis drug, Lialda.
In response, Shire along with Cosmo Technologies Ltd., and Guiliani International Ltd. filed a suit against Watson Pharma in the U.S. District Court for the Southern District of Florid, to prevent the generic company from commercializing … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards